BlackThorn receives $8 Million to advance KOR Antagonist Program
BlackThorn Therapeutics announced that it has received a grant from the National Institute of Neurological Disorders and Stroke (NINDS) of the National Institutes of Health (NIH). The grant is funded as part of the Blueprint Neurotherapeutics Network (BPN) of the NIH Blueprint for Neuroscience Research, a collaboration of NIH Institutes and Centers that supports research on the nervous system with the goal of developing new neurotherapeutic drugs. This award is worth up to $8 million to support BlackThorn’s development of kappa opioid receptor (KOR) antagonists.
“Recent research suggests that KOR is a novel therapeutic target for disorders associated with stress, including migraine,” said Bill Martin, Ph.D., chief scientific officer of BlackThorn. “For KOR antagonists to have therapeutic potential, they must be potent and highly selective and have reversible pharmacology and excellent brain penetration. To date, BlackThorn’s KOR antagonists have demonstrated these properties, which helped the company receive this prestigious grant award. Research support from the NINDS will help us discover and evaluate KOR antagonists with the goal of developing them for multiple therapeutic applications, including migraine prophylaxis.”
“Migraine is a prevalent and disabling neurological disorder that severely impacts patients’ quality of life,” said Charles L. Cywin, Ph.D., program director of BPN. “We look forward to building on BlackThorn’s capabilities in working with the KOR pathway and to potentially targeting the KOR to develop treatments for migraine relief.”
“BlackThorn has worked on the KOR pathway since its inception and is well positioned to leverage its medicinal chemistry expertise toward migraine prophylaxis,” said Rob Jones, Ph.D., the principal investigator on the grant, who will work in collaboration with co-investigators Professor Edward Roberts, Ph.D., and Professor Hugh Rosen, M.D., Ph.D., both of The Scripps Research Institute, and Professor Frank Porreca, Ph.D., of the University of Arizona Health Sciences. Dr. Jones added, “Preliminary data suggest that stress can induce features that are consistent with clinical observations of migraine pain in a novel animal model of medication overuse headache induced by a period of prior exposure to triptan drugs. Central KOR blockade appears to counteract this effect in part via a CGRP-dependent mechanism.”
Approximately 40 million Americans suffer from migraines, and the disease costs the United States about $36 billion annually in healthcare costs and lost productivity, according to the Migraine Research Foundation.
About the KOR Pathway in Neurological Disorders
The KOR pathway – located within brain regions that regulate the negative effects of stress on behavior – recently has emerged as a novel therapeutic target for the treatment of disorders related to stress, including depression, substance abuse disorder and migraine. The anatomical and physiological roles of the KOR suggest that blocking it could be therapeutically useful for these disorders.
About BlackThorn’s KOR Antagonist Program
BlackThorn is building a proprietary KOR antagonist program through a partnership with The Scripps Research Institute. Preclinical studies of the compounds in BlackThorn’s KOR program have shown potency, selectivity and reversibility, and additional studies are ongoing. BlackThorn plans to use the Blueprint grant to develop novel compounds and optimize their KOR affinity, selectivity, reversibility, oral availability, brain/plasma ratio, and drug metabolism and pharmacokinetic profiles for potential therapeutic use in stress-related migraine prophylaxis, alongside BlackThorn’s other KOR programs, which are targeting neurobehavioral and neurologic disorders.